These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38500216)

  • 21. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress in drug development for fibrodysplasia ossificans progressiva.
    Meng X; Wang H; Hao J
    Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
    Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
    J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW; Peck SH; Kaplan FS; Shore EM
    Dev Biol; 2021 Feb; 470():136-146. PubMed ID: 33217406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP).
    Billings PC; Fiori JL; Bentwood JL; O'Connell MP; Jiao X; Nussbaum B; Caron RJ; Shore EM; Kaplan FS
    J Bone Miner Res; 2008 Mar; 23(3):305-13. PubMed ID: 17967130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
    Towler OW; Shore EM; Kaplan FS
    Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.
    Aykul S; Huang L; Wang L; Das NM; Reisman S; Ray Y; Zhang Q; Rothman N; Nannuru KC; Kamat V; Brydges S; Troncone L; Johnsen L; Yu PB; Fazio S; Lees-Shepard J; Schutz K; Murphy AJ; Economides AN; Idone V; Hatsell SJ
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35511419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
    Davis AJ; Brooijmans N; Brubaker JD; Stevison F; LaBranche TP; Albayya F; Fleming P; Hodous BL; Kim JL; Kim S; Lobbardi R; Palmer M; Sheets MP; Vassiliadis J; Wang R; Williams BD; Wilson D; Xu L; Zhu XJ; Bouchard K; Hunter JW; Graul C; Greenblatt E; Hussein A; Lyon M; Russo J; Stewart R; Dorsch M; Guzi TJ; Kadambi V; Lengauer C; Garner AP
    Sci Transl Med; 2024 May; 16(749):eabp8334. PubMed ID: 38809966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
    Lin H; Shi F; Gao J; Hua P
    Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
    Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
    J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1
    Maruyama R; Nguyen Q; Roshmi RR; Touznik A; Yokota T
    Nucleic Acid Ther; 2022 Jun; 32(3):185-193. PubMed ID: 35085461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granting immunity to FOP and catching heterotopic ossification in the Act.
    Kaplan FS; Pignolo RJ; Shore EM
    Semin Cell Dev Biol; 2016 Jan; 49():30-6. PubMed ID: 26706149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.
    Kaplan FS; Al Mukaddam M; Stanley A; Towler OW; Shore EM
    Bone; 2020 Nov; 140():115539. PubMed ID: 32730934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fibrodysplasia ossificans progressiva and osteoimmunology].
    Katagiri T
    Clin Calcium; 2016 May; 26(5):691-8. PubMed ID: 27117614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling.
    Wang H; Lindborg C; Lounev V; Kim JH; McCarrick-Walmsley R; Xu M; Mangiavini L; Groppe JC; Shore EM; Schipani E; Kaplan FS; Pignolo RJ
    J Bone Miner Res; 2016 Sep; 31(9):1652-65. PubMed ID: 27027798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
    Shore EM; Kaplan FS
    Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva.
    de Ruiter RD; Wisse LE; Schoenmaker T; Yaqub M; Sánchez-Duffhues G; Eekhoff EMW; Micha D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.